For Hodgkin Lymphoma, Perifosine Plus Sorafenib May Be Safe and Effective

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Clinical Cancer Research, combination therapy with perifosine and sorafenib may be effective and safe for the treatment of patients with relapsed or refractory Hodgkin lymphoma.

For the study, investigators sought to determine the safety and efficacy of the combination therapy in patients with relapsed or refractory lymphoproliferative diseases. Researchers enrolled 40 patients, each of which received perifosine 50mg twice daily for 1 month. Sorafenib 400mg twice daily was added to perifosine in patients who had achieved less than a partial response after the first month, and patients received combination therapy until disease progression or unacceptable toxicity.

Of the 25 patients with Hodgkin lymphoma, a partial response rate of 28% was observed. Among all patients, a median overall survival of 16 months and a progression-free survival of 5 months were observed. The most common adverse effects were hand-foot skin reaction, joint pain, diarrhea, anemia, and thrombocytopenia.

Perifosine is an investigational Akt and PI3K inhibitor being studied for a variety of cancer types. Sorafenib, a tyrosine kinase inhibitor, was initially approved by the U.S. Food and Drug Administration in 2005. It is approved for the treatment of patients with unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

Nivolumab Designated Breakthrough Therapy for Hodgkin Lymphoma
Combination therapy with perifosine and sorafenib effective and safe for Hodgkin lymphoma.

Purpose of this study is to evaluate safety and activity of perifosine and sorafenib combination therapy in patients with lymphoproliferative diseases. Perifosine and sorafenib combination therapy is feasible with manageable toxicity and demonstrates promising activity in patients with Hodgkin lymphoma.

The predictive value of pERK and pAKT should be confirmed in a larger patient cohort.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs